TrialBMC cancer2013
Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy.
Igor Bondarenko et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
51 papers cite it
this paperpooled ittrialcites it